Chemomab Therapeutics Debt-to-Assets Ratio Growth & History (CMMB)

Chemomab Therapeutics's debt-to-assets ratio was 0.00 for fiscal 2025.

View full Chemomab Therapeutics company overview

Chemomab Therapeutics annual debt-to-assets ratio history

Chemomab Therapeutics annual debt-to-assets ratio

Fiscal yearPeriod endedDebt-to-assets ratioChangeGrowth
20252025-12-310.00−0.02
20242024-12-310.020.00+7.93%
20232023-12-310.020.01+256.11%
20222022-12-310.00−0.00−6.76%
20212021-12-310.01−0.01−65.90%
20202020-12-310.02−0.04−72.33%
20192019-12-310.06−0.08−57.59%
20182018-12-310.13

Chemomab Therapeutics debt-to-assets ratio trends

Over the last five fiscal years, Chemomab Therapeutics's debt-to-assets ratio decreased from 0.02 to 0.00, a change of −0.02. The latest reported quarter, Q4 2025, shows 0.00.

About the metric

What the debt-to-assets ratio means

The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.

Calculation and source

How debt-to-assets is calculated

TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Chemomab Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about CMMB yet. Start the conversation.

Write the first post